Effects of mutations on HIV-1 infectivity and neutralization involving the conserved NNNT amino acid sequence in the gp120 V3 loop

FEBS Letters

Volumn 583, Issue 7, 2009, Pages 1201-1206

  Polzer, Svenja ^a   Müller, Harm ^a   Schreiber, Michael ^a  

^a BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

HIV; N linked glycosylation; Neutralization; V3 loop; Viral infectivity

Indexed keywords

GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; VIRUS RESISTANCE;

AMINO ACID MOTIFS; ANTIBODIES; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; GLYCOSYLATION; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 62849099645     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.03.010     Document Type: Article

References (30)

1. Leonard C.K., Spellman M.W., Riddle L., Harris R.J., Thomas J.N., and Gregory T.J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265 (1990) 10373-10382
2. Back N.K., Smit L., De Jong J.J., Keulen W., Schutten M., Goudsmit J., and Tersmette M. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199 (1994) 431-438
3. Schonning K., Jansson B., Olofsson S., and Hansen J.E. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. J. Gen. Virol. 77 (1996) 753-758
4. Polzer S., Dittmar M.T., Schmitz H., and Schreiber M. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 304 (2002) 70-80
5. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
6. de Parseval A., Bobardt M.D., Chatterji A., Chatterji U., Elder J.H., David G., Zolla-Pazner S., Farzan M., Lee T.H., and Gallay P.A. A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs. J. Biol. Chem. 280 (2005) 39493-39504
7. Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., and Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312 (1984) 763-770
8. Singer I.I., Scott S., Kawka D.W., Chin J., Daugherty B.L., De Martino J.A., Di Salvo J., Gould S.L., Lineberger J.E., Malkowitz L., Miller M.D., Mitnaul L., Siciliano S.J., Staruch M.J., Williams H.R., Zweerink H.J., and Springer M.S. CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J. Virol. 75 (2001) 3779-3790
9. Huang C.C., Lam S.N., Acharya P., Tang M., Xiang S.H., Hussan S.S., Stanfield R.L., Robinson J., Sodroski J., Wilson I.A., Wyatt R., Bewley C.A., and Kwong P.D. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317 (2007) 1930-1934
10. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., and Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 310 (2005) 1025-1028
11. Human Retroviruses and AIDS 1999: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Part VII: Global Variation in the HIV-1 V3 Region (Kuiken, C.L., Foley B., Hahn, B., Marx, P.A., McCutchan, F., Mellors, J.W., Mullins, J.I., Wolinsky, S., and Korber, B., Eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
12. Tian H., Lan C., and Chen Y.H. Sequence variation and consensus sequence of V3 loop on HIV-1 gp120. Immunol. Lett. 83 (2002) 231-233
13. Polzer S., Dittmar M.T., Schmitz H., Meyer B., Müller H., Kräusslich H.G., and Schreiber M. Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1. Glycobiology 11 (2001) 11-19
14. Losman B., Biller M., Olofsson S., Schønning K., Lund O.S., Svennerholm B., Hansen J.E., and Bolmstedt A. The N-linked glycan of the V3 region of HIV-1 gp120 and CXCR4-dependent multiplication of a human immunodeficiency virus type 1 lymphocyte-tropic variant. FEBS Lett. 454 (1999) 47-52
15. McCaffrey R.A., Saunders C., Hensel M., and Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J. Virol. 78 (2004) 3279-3295
16. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W., Robinson J., Van Ryk D., Wang L., Burton D.R., Freire E., Wyatt R., Sodroski J., Hendrickson W.A., and Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 (2002) 678-682
17. Clevestig P., Pramanik L., Leitner T., and Ehrnst A. CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site. J. Gen. Virol. 87 (2006) 607-612
18. Malenbaum S.E., Yang D., Cavacini L., Posner M., Robinson J., and Cheng-Mayer C. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J. Virol. 74 (2000) 11008-11016
19. Schønning K. Antibody neutralization of human immunodeficiency virus type 1 (HIV-1). APMIS Suppl. 111 (2003) 1-42
20. Wolk T., and Schreiber M. N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med. Microbiol. Immunol. 195 (2006) 165-172
21. Johnson W.E., Sanford H., Schwall L., Burton D.R., Parren P.W., Robinson J.E., and Desrosiers R.C. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J. Virol. 77 (2003) 9993-10003
22. Schreiber M., Petersen H., Wachsmuth C., Müller H., Hufert F.T., and Schmitz H. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum. J. Virol. 68 (1994) 3908-3916
23. Niedrig M., Rabanus J.P., L'Age Stehr J., Gelderblom H.R., and Pauli G. Monoclonal antibodies directed against human immunodeficiency virus (HIV) gag proteins with specificity for conserved epitopes in HIV-1, HIV-2 and simian immunodeficiency virus. J. Gen. Virol. 69 (1988) 2109-2114
24. Chesebro B., and Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J. Virol. 62 (1988) 3779-3788
25. Johnson V.A., and Byington R.E. Quantitative assays for virus infectivity. In: Aldovini A., and Walker B. (Eds). Techniques of HIV Research (1990), Stockton Press, New York, NY 53-83
26. Nolan K.M., Jordan A.P., and Hoxie J.A. Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors. J. Virol. 82 (2008) 664-673
27. Low A.J., Marchant D., Brumme C.J., Brumme Z.L., Dong W., Sing T., Hogg R.S., Montaner J.S., Gill V., Cheung P.K., and Harrigan P.R. CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. AIDS Res. Hum. Retroviruses 24 (2008) 219-228
28. Schreiber M., Wachsmuth C., Müller H., Hagen C., Schmitz H., and van Lunzen J. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression. J. Gen. Virol. 77 (1996) 2403-2414
29. Schreiber M., Müller H., Wachsmuth C., Laue T., Hufert F.T., Van Laer M.D., and Schmitz H. Escape of HIV-1 is associated with lack of V3 domain-specific antibodies in vivo. Clin. Exp. Immunol. 107 (1997) 15-20
30. Pollakis G., Kang S., Kliphuis A., Chalaby M.I., Goudsmit J., and Paxton W.A. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol. Chem. 276 (2001) 13433-13441